Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery-Reference-Cited by-同舟云学术

Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery

Published:2018-03-12 Issue:5 Volume:15 Page:1755-1765
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Rashid Jahidur¹,Nahar Kamrun¹,Raut Snehal¹,Keshavarz Ali¹,Ahsan Fakhrul¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 Coulter Drive, Amarillo, Texas 79106, United States

Funder

National Heart, Lung, and Blood Institute

Cardiovascular Medical Research and Education Fund

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.7b01003

Reference51 articles.

1. Combination Therapy in Pulmonary Arterial Hypertension

2. Treatment of pulmonary arterial hypertension in children

3. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension

4. Initial dual oral combination therapy in pulmonary arterial hypertension

5. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review;International Journal of Nanomedicine;2024-02

2. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01

3. Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies;Journal of Controlled Release;2024-01

4. Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension;Pharmaceuticals;2023-11-28

5. An evolving perspective on novel modified release drug delivery systems for inhalational therapy;Expert Opinion on Drug Delivery;2023-02-16